About

The University of Queensland’s Institute for Molecular Bioscience (IMB) is a global leader in multidisciplinary life sciences research, bringing together 500 researchers from across the globe for disease discovery, application and sustainable futures.

Company details

Company The University of Queensland’s Institute for Molecular Bioscience

Service Biotechnology

Websitewww.uniquest.com.au

Formed in 2000 as an initiative of The University of Queensland, the Queensland and Australian governments and private philanthropy, IMB is one of the largest life sciences institutes in the Asia-Pacific region.

Institute scientists use a range of model systems and facilities to advance their research in chemistry and structural biology, genomics of development and disease, and in cell biology and molecular medicine.

IMB’s combination of life, pharmacological and chemical researchers means it can take life science discoveries from genome to drug design and application – for health, disease and for the sustainability of our cities, fuels and foods.

IMB is proud of its strong reputation as a generator of new knowledge. With 66 patents and 11 spin-outs to our name, IMB has a strong record of economic development, impact and innovation through partnership.

Our offering – ASIC1a inhibitor for stroke and acute coronary syndrome

Heart disease is the leading cause of death in the USA, and there are no approved therapeutic options to treat the damage to the heart that results from prolonged ischemia.

Stroke is the second leading cause of death worldwide, and the leading cause of long-term disability. There are no FDA-approved therapeutics to specifically protect and salvage neuronal tissue post-stroke.

There is a clear unmet clinical need for both a cardioprotective and neuroprotective stroke drug with a broad safety profile and long therapeutic time window.

IMB researchers have developed a potent and selective peptide inhibitor (termed Hi1a) of acid-sensing ion channel 1a (ASIC1a), a therapeutic target in acute cardiac myoprotection and acute stroke neuroprotection. Hi1a is a strong candidate for further preclinical testing and ultimately progression into the clinic.